A206650 logo

EuBiologics Co., Ltd. Stock Price

KOSDAQ:A206650 Community·₩444.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A206650 Share Price Performance

₩12,120.00
-4290.00 (-26.14%)
₩12,120.00
-4290.00 (-26.14%)
Price ₩12,120.00

A206650 Community Narratives

There are no narratives available yet.

Snowflake Analysis

Acceptable track record and slightly overvalued.

1 Risk
2 Rewards

EuBiologics Co., Ltd. Key Details

₩96.0b

Revenue

₩0

Cost of Revenue

₩96.0b

Gross Profit

₩71.2b

Other Expenses

₩24.9b

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
678.52
100.00%
25.89%
0%
View Full Analysis

About A206650

Founded
2010
Employees
n/a
CEO
Yeong-Ok Baik
WebsiteView website
eubiologics.com

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein vaccine under the rCRM197 name; and biopharmaceutical contract research and manufacturing, and contract testing services. Further, the company engages in the development of and support for the manufacturing technologies of biomedicines. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Recent A206650 News & Updates

Recent updates

No updates